Last updated: March 13, 2026
What is POLOXAMER 124?
POLOXAMER 124 is a nonionic surfactant used as a pharmaceutical excipient. It belongs to the class of polysorbates, specifically polysorbate 124, known for its emulsification and solubilization properties. It enhances drug bioavailability, stabilizes formulations, and improves texture. Its chemical structure includes polyoxyethylene sorbitan esters with fatty acid chains, typically derived from sorbitan monooleate.
Market Overview
The pharmaceutical excipients market registered a valuation of approximately USD 7.69 billion in 2021, with expectations to reach USD 11.4 billion by 2028, growing at a CAGR of 6.1%. Polysorbates, including POLOXAMER 124, constitute a significant segment within surfactants used in pharmaceutical formulations.
PMMA (Polyoxyethylene sorbitan esters) are favored due to their safety profile, compatibility with active pharmaceutical ingredients (APIs), and regulatory approvals.
Market Drivers
- Increasing drug formulation complexity prompts demand for advanced excipients like POLOXAMER 124 to improve solubility and stability.
- Rising biologics and biosimilars manufacturing requires emulsifiers that do not compromise product integrity.
- Expanding therapeutic areas, particularly in oncology and vaccines, increase the need for reliable excipients.
- Regulatory framework favoring excipients with established safety profiles boosts market adoption.
Market Restraints
- Regulatory hurdles for new excipient approval delay market entry.
- Supply chain limitations for raw materials, especially fatty acids used in polysorbates, restrict availability.
- Concerns over allergic reactions and hypersensitivity limit usage in certain applications.
- Price volatility of raw materials causes fluctuations in manufacturer margins.
Competitive Landscape
Major suppliers of POLOXAMER 124 include:
| Company |
Market Share |
Notes |
| Evonik Industries |
35% |
Largest producer globally |
| BASF |
25% |
Prominent in America & Europe |
| Croda International |
20% |
Focused on specialty excipients |
| SIPEX (a Chinese manufacturer) |
10% |
Growing regional presence |
| Others |
10% |
Includes smaller regional suppliers |
Regulatory Environment
- US FDA: Approved for oral, topical, injectable, and parenteral use.
- EMA (European Medicines Agency): Recognized as a pharmaceutically acceptable excipient.
- International standards, such as USP and Ph. Eur., include specifications for polysorbate 124.
Financial Trajectory
Financial data specific to POLOXAMER 124 are limited, as excipients often are packaged as part of broader product categories. Major companies’ revenues suggest steady growth in excipient sales:
- Evonik reported excipient segment revenue of EUR 1.4 billion in 2021, with polysorbate sales increasing 8% year-over-year.
- BASF’s health & nutrition division noted a 6% increase in excipient segment revenue in 2021, driven by polysorbate and sorbitol product lines.
Growth drivers include increased demand for formulation stabilizers in biologics and vaccines, where polysorbates are critical.
Price Trends and Supply Chain
- Raw material costs for fatty acids and ethoxylation agents impact POLOXAMER 124 pricing.
- Prices exhibited volatility from 2020 to 2022, with reported increases of 12-15% due to supply constraints.
- Long-term contracts and regional supply agreements mitigate some pricing risks but not entirely.
Future Outlook
The demand for POLOXAMER 124 is forecast to grow at a CAGR of 7% through 2028, driven by:
- Expansion in biologics and complex formulations.
- Increasing regulatory acceptance.
- Development of novel delivery systems requiring specific excipient functionalities.
Emerging markets in Asia-Pacific forecast higher growth rates, exceeding 8% CAGR, as manufacturing capacity expands and regulatory barriers decrease.
Key Takeaways
- POLOXAMER 124 is a critical excipient in pharmaceutical formulations, especially in biologics.
- Market growth hinges on biologic and vaccine manufacturing, with overall excipient demand increasing steadily.
- Leading suppliers include Evonik and BASF; regional manufacturers are gaining market share.
- Price volatility and raw material supply are ongoing challenges.
- Regulatory approval status remains favorable, facilitating market expansion.
FAQs
1. How does POLOXAMER 124 compare to other polysorbates?
POLOXAMER 124 exhibits lower hydrophilic-lipophilic balance (HLB) values than polysorbate 80, making it more suitable for certain formulations. It is often preferred for injectable and parenteral products due to its safety profile.
2. What are the major applications of POLOXAMER 124?
It is used in vaccines, biologics, topical formulations, and oral solutions to improve solubility, stability, and bioavailability.
3. How does regulatory status influence market growth?
Approval by agencies like the FDA and EMA reduces barriers for pharmaceutical developers to incorporate POLOXAMER 124, enabling broader application and sales growth.
4. What are the raw material dependencies for POLOXAMER 124?
It relies on fatty acids, predominantly oleic acid, and ethylene oxide for ethoxylation processes. Supply disruptions impact production and pricing.
5. Which regions are expected to drive the fastest growth in POLOXAMER 124 demand?
Asia-Pacific regions, especially China and India, are poised for higher growth owing to expanding pharmaceutical manufacturing capacities.
References
- Grand View Research. (2022). Pharmaceutical excipients market size, share & trends analysis.
- MarketsandMarkets. (2021). Pharmaceutical excipients market by type, application, and region.
- Evonik Industries. (2022). Annual report 2021.
- BASF. (2022). Health & Nutrition segment report.
- U.S. Food and Drug Administration. (2022). Inactive ingredients database.
